DUBLIN--(BUSINESS WIRE)--The "Legionella Testing Market by Test Type (Culture, Urinary Antigen Test, DFA, PCR), Application (Water & IVD Testing (Urine, Blood)), End User (Hospitals, Clinics, Diagnostic Labs, Water Treatment Industries), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The global legionella testing market is projected to reach USD 439 million by 2027 from USD 296 million in 2022, at a CAGR of 8.2% during the forecast period.
Growth in this market is mainly driven by the rising geriatric population coupled with the increasing prevalence of legionella-related illness, and rising demand for rapid diagnostics.
The PCR segment accounted for the highest growth rate in the legionella testing market, by test type, during the forecast period.
The legionella testing market is segmented into culture methods, urinary antigen tests, direct fluorescent antibody tests, and PCR based on product. In 2021, the PCR segment accounted for the highest growth rate in the legionella testing market. Market growth can largely be attributed to its speed, versatility, and simplicity.
The water & Other Industries segment accounted for the highest CAGR.
Based on the end user, the legionella testing market has been segmented into hospitals, diagnostic laboratories, water & other industries, and other end user. In 2021, the water & other industries segment accounted for the highest growth rate. This can be attributed to the rising population and urbanization, and the increased demand for new water resources
Asia Pacific: The fastest-growing region legionella testing market.
The global legionella testing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as government efforts to increase awareness about early disease diagnosis and regular health check-ups
Market Dynamics
Drivers
- Rising Incidence of Pneumonia and Legionella-Related Illnesses
- Increasing Demand for Rapid Advanced Diagnostic Technologies
- Technological Advancements in Bacterial Testing
- Stringent Regulations for Regular Water Testing
Restraints
- Lack of Reimbursement Policies
Opportunities
- Opportunities in Growing Economies
- Legal Requirements for Water Testing
Challenges
- Difficulties in Detection
- Limited Awareness in Underdeveloped Countries
- High Health Costs Associated with Legionella
Companies Mentioned
- Accepta
- Alere (Abbott)
- Aquacert
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- Bioalert Solutions
- Biomerieux Sa
- DTK Water
- Eiken Chemical
- Environmental Safety Technologies
- Eurofins Scientific
- Genomadix
- Hologic
- Hydrosense
- Idexx Laboratories
- Luminultra Technologies
- Merck KGaA
- Pacific Water Technology
- Pall Corporation (Danaher)
- Phigenics, LLC
- Pro-Lab Diagnostics
- Qiagen
- Quidel Corporation
- Roche Diagnostics
- Sens Solutions
- Takara Bio
- Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/r/dwq3au
